Vanqua Bio to Present Pre-Clinical Data on VQ-101, a Novel GCase Activator For The Treatment of GBA-Parkinson’s Disease
CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, which will be held in Lisbon, Portugal and virtually from March 5-9.
- CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, which will be held in Lisbon, Portugal and virtually from March 5-9.
- “We created Vanqua Bio with the aim of developing innovative therapies capable of effectively slowing or halting the progression of neurodegenerative disorders, including GBA-PD, which is the largest genetically defined subset of Parkinson’s disease,” said Jim Sullivan, PhD, Co-founder and Chief Executive Officer of Vanqua Bio.
- “We look forward to discussing the pre-clinical characterization of our clinical stage program, VQ-101, a brain-penetrant small molecule allosteric activator of GCase.
- Furthermore, we look forward to sharing data on the development of a live cell GCase activity assay, which has enabled measurement of GCase activation in our preclinical systems and will be used to assess GCase activation in our Phase 1 trial.”
Title: VQ-101, A Small Molecule Allosteric Activator of Glucocerebrosidase, Demonstrates Neuroprotection in Models of GBA-Parkinson’s Disease and Robust In-Vivo Target Engagement